267 related articles for article (PubMed ID: 28713676)
1. Immunotherapy for malignant pleural mesothelioma: current status and future directions.
Dozier J; Zheng H; Adusumilli PS
Transl Lung Cancer Res; 2017 Jun; 6(3):315-324. PubMed ID: 28713676
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
Murthy V; Katzman D; Sterman DH
Clin Respir J; 2019 May; 13(5):272-279. PubMed ID: 30810270
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
Borgeaud M; Kim F; Friedlaender A; Lococo F; Addeo A; Minervini F
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902544
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies in malignant pleural mesothelioma.
Cinausero M; Rihawi K; Cortiula F; Follador A; Fasola G; Ardizzoni A
Crit Rev Oncol Hematol; 2019 Dec; 144():102815. PubMed ID: 31670225
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapy clinical trials in malignant pleural mesothelioma.
Tano ZE; Chintala NK; Li X; Adusumilli PS
Ann Transl Med; 2017 Jun; 5(11):245. PubMed ID: 28706913
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.
Rovers S; Janssens A; Raskin J; Pauwels P; van Meerbeeck JP; Smits E; Marcq E
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327475
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).
Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C
Mol Clin Oncol; 2022 Apr; 16(4):89. PubMed ID: 35251640
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy and malignant mesothelioma: clinical perspectives].
Grégoire M; Ebstein F
Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
[TBL] [Abstract][Full Text] [Related]
9. Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.
Belderbos RA; Vroman H; Aerts JGJV
Front Oncol; 2020; 10():777. PubMed ID: 32582537
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
Terenziani R; Zoppi S; Fumarola C; Alfieri R; Bonelli M
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199722
[TBL] [Abstract][Full Text] [Related]
11. Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma.
Rondon L; Fu R; Patel MR
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296902
[TBL] [Abstract][Full Text] [Related]
12. Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.
Facchinetti F; Marabelle A; Rossi G; Soria JC; Besse B; Tiseo M
J Thorac Oncol; 2016 Nov; 11(11):1819-1836. PubMed ID: 27288978
[TBL] [Abstract][Full Text] [Related]
13. Treatment of malignant pleural mesothelioma: current status and future directions.
Dhalluin X; Scherpereel A
Monaldi Arch Chest Dis; 2010 Jun; 73(2):79-85. PubMed ID: 20949774
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and radiation therapy for malignant pleural mesothelioma.
Alley EW; Katz SI; Cengel KA; Simone CB
Transl Lung Cancer Res; 2017 Apr; 6(2):212-219. PubMed ID: 28529903
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.
Calabrò L; Morra A; Cornelissen R; Aerts J; Maio M
Cancer Immunol Immunother; 2018 Aug; 67(8):1317-1324. PubMed ID: 29943157
[TBL] [Abstract][Full Text] [Related]
16. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.
Davis A; Ke H; Kao S; Pavlakis N
Lung Cancer (Auckl); 2022; 13():1-12. PubMed ID: 35264891
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
Klampatsa A; Haas AR; Moon EK; Albelda SM
Cancers (Basel); 2017 Sep; 9(9):. PubMed ID: 28862644
[TBL] [Abstract][Full Text] [Related]
18. A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology.
Bibby AC; Zahan-Evans N; Keenan E; Comins C; Harvey JE; Day H; Rahman NM; Fallon JE; Gooberman-Hill R; Maskell NA
Pilot Feasibility Stud; 2022 Sep; 8(1):196. PubMed ID: 36057634
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
[TBL] [Abstract][Full Text] [Related]
20. Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.
Wu L; de Perrot M
Transl Lung Cancer Res; 2017 Jun; 6(3):325-334. PubMed ID: 28713677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
